Paragon's hub-and-spoke biotech model yields another reverse merger
BioPharma
Source: biopharmadive.com
Stay updated with breaking news from Dive Brief. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.
Construction industry news, trends and jobs for building professionals who want mobile-friendly content.